CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.31 CNY | -0.30% |
|
+3.98% | -13.85% |
| Apr. 10 | Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
| Apr. 03 | Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Companyâs products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -13.85% | 767M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 002907 Stock
- News Chongqing Pharscin Pharmaceutical Co., Ltd.
- Chengxin Rating Terminates Pharscin Pharma’s Credit Ratings After Bond Redemption
